摘要SiewertⅡ型食管胃结合部腺癌（AEG）发病率逐年上升，由于其解剖部位及生物学行为的特殊性，AEG的治疗仍存在诸多争议。争议焦点主要集中在淋巴结清扫范围、食管切缘和胃切除范围、术后消化道重建方式的选择等方面。微创时代的来临，将SiewertⅡ型AEG的诊疗带入了一个逐步完善和规范的阶段，我国亦通过多中心试验（CLASS-10等）在积极探索微创外科在AEG治疗中的价值。相信在多项临床研究、基础实验研究以及大型前瞻性临床研究积极开展的基础上，通过加强各学科之间的沟通与合作，以及新技术的创新应用，可为患者带来更大的生存获益。

abstractsThe incidence of Siewert type II adenocarcinoma of the esophagogastric junction (AEG) is increasing year by year. Due to its special anatomical location and biological behavior, the treatment of AEG is still controversial in terms of lymph node dissection, the esophageal resection margin, range of gastrectomy, and the choice of reconstruction modality for postoperative gastrointestinal tract. The advent of the minimally invasive era has brought the treatment of Siewert type II AEG to a stage of gradual improvement and standardization. Experts of China are also actively exploring the value of minimally invasive surgery in the treatment of AEG through multicenter trials (CLASS-10, etc.). It is believed that based on the active development of many clinical studies, basic experimental studies and large prospective clinical studies, the strengthening of communication and cooperation among various disciplines and the innovative application of new technologies can bring greater survival benefits to patients.